Oral hypoglycemics are involved in the current treatment therapy for type II diabetes mellitus. Continuous research on developing an improved class of oral hypoglycemic led to the development of SGLT2 inhibitors. Their unique mechanism of action made them most sought after the class of oral hypoglycemic. Various clinical studies have disclosed that SGLT2 inhibitors are devoid of many side effects compared to other classes of oral hypoglycemics. Discovery of these inhibitors began with the extensive studies on phlorizin, which provide the basic architecture for all the other glifozins i.e. SGLT2 inhibitors. Many molecules of this class such as dapagliflozin, canagliflozin, empagliflozin have been approved by USFDA for the treatment of type II diabetes mellitus. This work provides all the disclosed details of approved gliflozins and other gliflozins which are in development phase, in the conquest of finding "fool-proof" gliflozin.